

# Real-world safety and efficacy of rADAMTS13 prophylaxis in congenital thrombotic thrombocytopenic purpura: experience from Polish patients previously treated with fresh frozen plasma

## Authors

---

Jerzy Windyga,<sup>1,2</sup> Joanna Zdziarska,<sup>3</sup> Magdalena Górską-Kosicka,<sup>1</sup> Adela Gwozdowska,<sup>1</sup> Miłosz Jazdon,<sup>4</sup> Paweł Łaguna,<sup>5</sup> Maria Szczepańska,<sup>6</sup> Magdalena Wojdalska,<sup>7</sup> Danuta Pietrys,<sup>8</sup> Michał Taszner,<sup>9</sup> Michał Witkowski,<sup>10</sup> Beata Baran,<sup>2</sup> Wojciech Młynarski,<sup>7</sup>

<sup>1</sup>Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw; <sup>2</sup>Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw; <sup>3</sup>Department of Hematology and Internal Medicine, University Hospital in Cracow, Cracow; <sup>4</sup>Department of Pediatric Oncology, Hematology and Transplantology Poznan University of Medical Sciences Karol Jonscher Clinical Hospital Institute of Pediatrics, Poznan; <sup>5</sup>Department of Oncology, Pediatric Hematology, Transplantology and Pediatrics, Medical University of Warsaw, Warsaw; <sup>6</sup>Department of Pediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice;

<sup>7</sup>Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz; <sup>8</sup>Oncology and Hematology Department, University Children's Hospital of Cracow, Cracow; <sup>9</sup>Department of Haematology and Transplantology, Faculty of Medicine, Medical University of Gdansk, Gdansk and <sup>10</sup>General Hematology Department, Copernicus Memorial Hospital, Lodz, Poland

Correspondence:

JERZY WINDYGA - jwindyga@ihit.waw.pl

<https://doi.org/10.3324/haematol.2025.288561>

Received: July 16, 2025.

Accepted: September 19, 2025.

Early view: October 2, 2025.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

Supplementary Table 1. Laboratory parameters during 12 months of fresh frozen plasma therapy and 12 months following transition to rADAMTS13 prophylaxis

Parameter	N <sup>^</sup>	FFP	N	rADAMTS13	p
<b>All patients</b>					
Hemoglobin (g/dL)	17	13.0 (1.5)	23	13.8 (1.3)	0.02*
Platelets (×10 <sup>3</sup> /μL)	17	170.4 (78.3)	23	218.2 (64.2)	0.0003*
LDH (mg/dL)	17	335.5 (193.2)	23	210.0 (56.6)	0.0008 <sup>#</sup>
Bilirubin (mg/dL)	17	0.7 (0.4)	22 <sup>^</sup>	0.5 (0.4)	0.0001 <sup>#</sup>
Creatinine (mg/dL)	17	0.8 (0.3)	23	0.7 (0.3)	0.06 <sup>#</sup>
<b>Patients aged over 18 years</b>					
Hemoglobin (g/dL)	11	13.8 (1.2)	16	14.3 (1.2)	0.18*
Platelets (×10 <sup>3</sup> /μL)	11	153.8 (86.9)	16	207.9 (71.6)	0.007*
LDH (mg/dL)	11	287.1 (159.7)	16	203.3 (60.2)	0.054 <sup>#</sup>
Bilirubin (mg/dL)	11	0.8 (0.4)	15 <sup>^</sup>	0.6 (0.4)	0.008 <sup>#</sup>
Creatinine (mg/dL), mean (SD)	11	1.0 (0.3)	16	0.9 (0.3)	0.16 <sup>#</sup>
<b>patients aged 18 years or younger</b>					
Hemoglobin (g/dL), mean (SD)	6	11.5 (0.5)	7	12.7 (1.0)	0.04*
Platelets (×10 <sup>3</sup> /μL), mean (SD)	6	200.8 (52.6)	7	241.7 (37.0)	0.01*
LDH (mg/dL), mean (SD)	6	424.3 (232.1)	7	225.3 (47.9)	0.03 <sup>#</sup>
Bilirubin (mg/dL), mean (SD)	6	0.7 (0.3)	7	0.4 (0.3)	0.03 <sup>#</sup>

Creatinine (mg/dL), mean (SD)	6	0.6 (0.3)	7	0.5 (0.1)	0.50 <sup>#</sup>
-------------------------------	---	-----------	---	-----------	-------------------

Data are presented as mean (SD).

Abbreviations: FFP – fresh frozen plasma; LDH – lactate dehydrogenase

\*Paired t-test; <sup>#</sup>Wilcoxon matched-pairs signed rank test; <sup>^</sup>A reduced number attributable to incomplete or missing data

Supplementary Table 2. Hospitalizations during the last 12 months of fresh frozen plasma therapy and 12 months following transition to rADAMTS13 prophylaxis in all patients

Parameter	FFP	rADAMTS13	p
<b>All patients</b>			
Number of hospitalizations	17.2 (12.6)	0.7 (1.2)	<0.0001
Days of hospitalization	24.8 (16.1)	0.8 (1.6)	<0.0001
Number of exacerbation-related hospitalizations	0.7 (1.5)	0.0 (0.2)	0.049
Days of exacerbation-related hospitalizations	2.6 (6.0)	0.1 (0.4)	0.094
<b>&gt;18 years old</b>			
Number of hospitalizations	19.8 (14.6)	0.9 (1.3)	<0.0001
Days of hospitalization	24.7 (18.6)	1.1 (1.8)	<0.0001
Number of exacerbation-related hospitalizations	0	0.1 (0.3)	0.99
Days of exacerbation-related hospitalizations	0	0.1 (0.5)	0.99
<b>≤18 years old</b>			
Number of hospitalizations	12.9 (7.1)	0	<0.0001
Days of hospitalization	25.0 (11.9)	0	<0.0001
Number of exacerbation-related hospitalizations	1.7 (2.2)	0	0.07

Days of exacerbation-related hospitalizations	6.7 (8.4)	0	<0.0001
---	-----------	---	---------

Data are presented as mean (SD).